Search

everythinglearnresearchcommunity

for

Search:↓

Anagenica.com has poor customer service but delivers quality hair loss products like liposomal dutasteride. OP recommends ordering directly from Farmacia Tristiana for better service.

Hair systems are a popular solution for hair loss, offering impressive transformations with manageable maintenance and cost. Some users prefer hair systems over medications like Minoxidil or Finasteride, while others express concerns about the permanence and visibility of these systems.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.

The user shared their hair loss treatment progress using topical products like exosomes, fluridil, Kx826, and topical dutasteride, avoiding oral finasteride and dutasteride due to side effects. They found exosomes from Creative Biolabs most effective and also used topical probiotics, noting improvements without significant side effects.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

Microneedling with exosomes is being considered for hair regrowth, but concerns exist about their effectiveness and safety, especially since exosomes degrade quickly and lack FDA approval. The user is seeking alternatives for non-responders to minoxidil and dutasteride, as exosomes may not provide additional benefits.

Combining pyrilutamide and alfatradiol might be as effective as finasteride for hair maintenance. The user plans to try this combination alongside minoxidil and keto shampoo, hoping for improved hair thickness.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

Potential treatments for hair loss, including Minoxidil, finasteride, RU58841 and various upcoming pharmaceuticals, gene editing and cloning. It is suggested that a cure, if found, would be highly profitable due to the large number of people affected by hair loss globally.

A user shares optimism about combating male pattern baldness using oral and topical minoxidil, highlighting the advancements in treatments available today. Another user agrees, noting that early treatment can yield good results, and mentions the availability of affordable hair transplants.

The user has seen significant hair regrowth using topical minoxidil and dutasteride, with better results than finasteride alone. Despite concerns about hairline and temporal peaks, others believe a hair transplant is unnecessary due to the current hair condition.

Getting a hair transplant without using finasteride or dutasteride for at least two years can waste donor hair, as these medications can lead to significant hair regrowth in areas like the crown and mid-scalp. Delaying a transplant allows for better results by maximizing natural regrowth and preserving donor hair for more needed areas.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Hair transplants can initially yield good results, but native hair is more reliable, and transplanted hair may still be lost over time. Early intervention with treatments like topical finasteride and minoxidil is recommended, but it's important to start with lower doses and manage expectations realistically.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The user shared their 7.5-month post-hair transplant results, mentioning they have been using finasteride and oral minoxidil. The conversation includes mixed reactions, with some users complimenting the results and others critiquing the hairstyle and presentation.

Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The user shared a positive update on their hair transplant journey one year after the procedure in Turkey, where they received 4,350 grafts. They started taking finasteride at the 6-month mark and also use biotin, B6, B12, and scalp oils to support hair growth.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.

The conversation is about sourcing RU58841 for hair loss treatment in Australia and discusses the lack of effective alternatives. Alternatives mentioned include Kx826, fluridil, cb, alfatradiol, and topical spiro, but they are considered weak compared to RU58841.